SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmion
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tuck10/31/2007 11:33:04 AM
  Read Replies (1) of 22
 
Pharmion has been on a tear since the Vidaza data came out. MOGN's earnings seemed to indicate that Dacogen sales weren't much affected. Meanwhile, Satraplatin showed no benefit in OS today, which sent GPCB and SPPI tumbling. But PHRM is up. Wondering why the disconnect. PHRMy could still be liable for some dough to SPPI -- arbitration should wind up soon -- and they were to sell Satraplatin in the EU, where it's future is only slightly less in doubt than it is here.

Folks must be anticipating blow out earnings. Only explanation I can think of.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News